Olink Services Provided by ISB

ISB teams up with Olink® to bring you the most advanced products and services for protein biomarker discovery.

ISB is a leader in biomedical scientific research working at the cutting edge of advancements in human health and personalized medicine. We have more than a decade of experience using Olink data for biomarker discovery and validation to study disease areas like cardiovascular disease, cancer and neurodegenerative disease. We have also done pioneering research on healthy populations. Our expertise makes us an ideal partner to advance your proteomic research.

Get a quote→

Why Choose Us?


When you choose ISB as your assay provider, you can opt to capitalize on batch continuity and longitudinal data comparability enabled by our in-house pre-aliquoted bridge plasma samples pooled from 60 healthy individuals.


Given our deep expertise in ‘omics study design, data analysis and integration, we are equipped to offer experimental design and data analysis to your next project.


We offer both Olink® Target 96 and Olink® Explore capabilities, complete with sample library preparation.




Olink Logo
Olink® Explore

The Olink Explore is a high-multiplex, high-throughput protein biomarker platform that uses Proximity Extension Assay (PEA) technology coupled with an innovative new readout methodology based on Next Generation Sequencing (NGS) using Illumina’s NextSeq 2000. Explore can quantify 384 to 3,072 proteins in a single run.


Olink® Target 96

Olink Target 96 panels are able to achieve a high level of multiplexing while maintaining exceptional data quality thanks to Olink’s proprietary PEA technology with a qPCR-based readout using Fluidigm’s Biomark HD. Each biomarker is addressed by a matched pair of antibodies, coupled to unique, partially complementary oligonucleotides, and measured by quantitative real-time PCR. Target 96 is available for more than a dozen panels, including neurology, inflammation, cardiovascular disease, and oncology


What’s Next?

Augment your plate design with additional pooled technical control samples and bridge your samples to our growing in-house population of healthy control individuals. This enables flexible in silico designs that preserve the continuity of data over time and allow for synthetic cohort matching.

ISB has extensive experience in multi-omic research on healthy individuals from wellness cohorts as well as specific disease states. We are proud to have contributed part of our unique dataset of N=300 healthy control individuals to be integrated into Olink’s newest line of 3KN products and the accompanying Olink® Insight software.

High-Impact ISB Publications Utilizing Olink Datasets

Su Y, Chen D, Yuan D, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183(6):1479–1495.e20. doi:10.1016/j.cell.2020.10.037.

Price ND, Magis AT, Earls JC, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017;35(8):747-756. doi:10.1038/nbt.3870.

Magis AT, Rappaport N, Conomos MP, et al. Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis. Sci Rep. 2020;10(1):16275-16276. doi:10.1038/s41598-020-73451-z.